FiND study showed that the news sentiment for 3 drug-makers from top 25 pharma companies consistently remained below the industry average for the past 12-months. FDC, Sun Pharma Advanced Research and Caplin Point Laboratories were 3 companies whose short-term, medium-term and long-term news sentiment consistently stayed below the industry average for the past 12-months.
In our view, below industry average news sentiment for a prolonged period of time does not augur well for the company. Corporate communications team can step up media engagement at the appropriate time by picking up early signals for deteriorating news coverage.
[Image 1: Short-term news sentiment (50-DMA)] Read the rest of this entry »
French drug-maker Sanofi faces risk to its 16% of revenues after its top-selling drug Lantus came under threat from the generic manufacturers. The fear of losing revenue from Lantus has forced Sanofi to defend its intellectual property rights. Recent news flow showed that the maker of Lantus drug filed several patent infringement suits against the generic manufacturers.
Lantus, an “Insulin glargine” (a long-acting basal insulin analogue), accounted for 16.4% of Sanofi’s net sales in 2016. Lantus consists of microcrystals, which slowly releases insulin over a period of 24 hours with a peak-less profile. This drug helps in controlling the blood sugar of diabetic people.
Lantus is one of the major drugs in the anti-diabetic segment. In 2015, Lantus accounted for ~17% of the global sales for anti-diabetic products.